Ligand ID: ASW


Drugbank ID:
DB00276
(Amsacrine)


Indication:
For treatment of acute myeloid leukaemia.

Get human targets for ASW in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'ASW' AND SARS-COV-2 / COVID-19 STRUCTURES

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 6
PRO A 108
GLY A 174
ALA A 129
GLN A 192
1.37A17.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 6
ARG B 131
GLY B 109
GLU B 240
GLN B 127
1.79A17.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6m3m NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO C 118
ARG C  89
ALA C  51
GLN C  59
1.34A11.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6m71 NSP12
(SARS-CoV-2)		4 / 7
PRO A 537
GLY A 345
ALA A 379
GLN A 357
1.42A21.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
PRO B 715
GLY C 885
ALA C 892
GLN C1036
1.41A21.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
ILE C 896
PRO C 897
GLY B1131
ALA C 903
1.14A21.56
None
None
NAG  B1305 ( 4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6vxs NSP3
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6vxs NSP3
(SARS-CoV-2)		4 / 7
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6vxs NSP3
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  47
ALA A 129
GLN A  62
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6vxs NSP3
(SARS-CoV-2)		4 / 7
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6vxs NSP3
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  47
ALA B 129
GLN B  62
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6vxs NSP3
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6vxs NSP3
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  50
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
ILE A1013
GLY A 769
ALA A1016
GLN C 957
1.15A21.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
PRO C 715
GLY C1046
ALA C1070
GLN C1036
1.47A21.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
ILE A 896
PRO A 897
GLY C1131
ALA A 903
1.16A21.44
None
None
NAG  C1310 (-3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
PRO A 715
GLY B 885
ALA B 892
GLN B1036
1.37A21.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6vyo NUCLEOPROTEIN
(SARS-CoV-2)		4 / 6
PRO B 117
ARG B  88
ALA B  50
GLN B  58
1.46A10.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 6
PRO B  68
GLY B  77
ALA B  81
GLN B 188
1.46A18.68
None
PEG  B 411 ( 3.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w61 NSP10
(SARS-CoV-2)		4 / 7
ILE B4352
PRO B4353
GLY B4380
ALA B4307
1.71A10.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 6
PRO A 108
GLY A 174
ALA A 129
GLN A 192
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  52
1.49A
AMP  A 201 ( 4.0A)
None
AMP  A 201 ( 3.5A)
AMP  A 201 ( 4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  50
1.53A
AMP  A 201 ( 4.0A)
None
AMP  A 201 ( 3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B  97
ALA B  50
1.51A
None
None
None
MES  B 201 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 7
PRO A 125
GLY A  47
ALA A 129
GLN A  62
1.80A10.06
None
None
AMP  A 201 ( 3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A  97
ALA A  50
1.48A
AMP  A 201 ( 4.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 7
ILE A 106
PRO A  98
GLY A  79
GLN A 118
1.76A10.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 7
PRO B 125
GLY B  47
ALA B 129
GLN B  62
1.76A10.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  47
ALA B 129
GLN B  62
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 7
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.54A10.06
None
AMP  A 201 ( 3.6A)
AMP  A 201 ( 3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.55A
None
AMP  A 201 ( 3.6A)
AMP  A 201 ( 3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 7
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B 130
ALA B  52
1.47A
None
None
MES  B 201 ( 3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B 130
ALA B  50
1.46A
None
None
MES  B 201 ( 3.4A)
MES  B 201 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  47
ALA A 129
GLN A  62
1.69A
None
None
AMP  A 201 ( 3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 7
ILE C 151
GLY C 160
ALA C 149
GLN B 269
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w9q 3C-LIKE PROTEINASE
PEPTIDE, NSP9 FUSION
(SARS-CoV-2)		4 / 7
ILE A  91
GLY A 100
ALA A  43
GLN A  -3
0.99A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wcf NSP3
(SARS-CoV-2)		4 / 7
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wcf NSP3
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  52
1.46A
None
None
MES  A 201 (-3.2A)
MES  A 202 (-4.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wcf NSP3
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A  97
ALA A  50
1.49A
None
None
None
MES  A 201 ( 3.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wcf NSP3
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  50
1.49A
None
None
MES  A 201 (-3.2A)
MES  A 201 ( 3.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wcf NSP3
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wcf NSP3
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  47
ALA A 129
GLN A  62
1.65A
None
MES  A 202 (-3.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wen NSP3
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  47
ALA A 129
GLN A  62
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wen NSP3
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wen NSP3
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A  97
ALA A  50
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wen NSP3
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  51
ALA A 129
GLN A  62
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wen NSP3
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  50
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wen NSP3
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  52
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wey NSP3
(SARS-CoV-2)		4 / 6
PRO A 329
GLY A 251
ALA A 333
GLN A 266
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wey NSP3
(SARS-CoV-2)		4 / 7
ILE A 227
PRO A 329
GLY A 301
ALA A 254
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wey NSP3
(SARS-CoV-2)		4 / 6
PRO A 329
GLY A 252
ALA A 333
GLN A 266
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wey NSP3
(SARS-CoV-2)		4 / 7
PRO A 329
GLY A 252
ALA A 333
GLN A 266
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wiq NSP8
(SARS-CoV-2)		4 / 7
ILE B 120
PRO B 121
ALA B 152
GLN B 158
1.20A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO B 309
GLY B 316
ALA A 308
GLN A 283
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO A 309
GLY A 316
ALA B 308
GLN B 283
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO E 309
GLY E 316
ALA F 308
GLN F 283
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO F 309
GLY F 316
ALA E 308
GLN E 283
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO C 309
GLY C 316
ALA D 308
GLN D 283
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO D 309
GLY D 316
ALA C 308
GLN C 283
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO C 309
GLY C 316
ALA D 308
GLN D 281
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
PRO B 117
ARG B  88
ALA B  50
GLN B  58
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO B 117
ARG B  88
GLY B 129
GLN B  58
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO D 117
ARG D  88
GLY D 129
GLN D  58
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO C 117
ARG C  88
ALA C  50
GLN C  58
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO C 117
ARG C  88
GLY C 129
GLN C  58
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO A 117
ARG A  88
ALA A  50
GLN A  58
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO D 117
ARG D  88
ALA D  50
GLN D  58
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO A 117
ARG A  88
GLY A 129
GLN A  58
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO B 117
ARG B  88
ALA B  50
GLN B  58
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 6
PRO A  68
GLY A  77
ALA A  81
GLN A 188
1.65A
None
EDO  A 406 ( 3.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PRO D 125
GLY D  47
ALA D 129
GLN D  62
1.62A
None
APR  D 201 (-4.2A)
APR  D 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.49A
None
APR  A 201 (-3.5A)
APR  A 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PRO D 125
GLY D  48
ALA D 129
GLN D  62
1.51A
None
APR  D 201 (-3.5A)
APR  D 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.53A
None
APR  B 201 (-3.4A)
APR  B 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE D  23
PRO D 125
GLY D  97
ALA D  50
1.48A
APR  D 201 (-3.8A)
None
None
APR  D 201 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.52A
None
APR  A 201 (-3.5A)
APR  A 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PRO C 125
GLY C  47
ALA C 129
GLN C  62
1.60A
None
APR  C 201 (-4.1A)
APR  C 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  47
ALA A 129
GLN A  62
1.58A
None
APR  A 201 (-4.1A)
APR  A 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE D  23
PRO D 125
GLY D 130
ALA D  50
1.41A
APR  D 201 (-3.8A)
None
APR  D 201 (-3.2A)
APR  D 201 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE C  23
PRO C 125
GLY C 130
ALA C  50
1.43A
APR  C 201 (-3.9A)
None
APR  C 201 (-3.0A)
APR  C 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  50
1.39A
APR  A 201 (-4.0A)
None
APR  A 201 (-3.5A)
APR  A 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE C  23
PRO C 125
GLY C  97
ALA C  50
1.50A
APR  C 201 (-3.9A)
None
None
APR  C 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE D  23
PRO D 125
GLY D 130
ALA D  52
1.48A
APR  D 201 (-3.8A)
None
APR  D 201 (-3.2A)
APR  D 201 ( 4.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PRO D 125
GLY D  48
ALA D 129
GLN D  62
1.55A
None
APR  D 201 (-3.5A)
APR  D 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B  97
ALA B  50
1.48A
APR  B 201 (-3.8A)
None
None
APR  B 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  52
1.49A
APR  A 201 (-4.0A)
None
APR  A 201 (-3.5A)
APR  A 201 ( 4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE C  23
PRO C 125
GLY C 130
ALA C  52
1.46A
APR  C 201 (-3.9A)
None
APR  C 201 (-3.0A)
APR  C 201 ( 4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B 130
ALA B  52
1.48A
APR  B 201 (-3.8A)
None
APR  B 201 (-3.3A)
APR  B 201 ( 4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B 130
ALA B  50
1.47A
APR  B 201 (-3.8A)
None
APR  B 201 (-3.3A)
APR  B 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.56A
None
APR  B 201 (-3.4A)
APR  B 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PRO C 125
GLY C  48
ALA C 129
GLN C  62
1.51A
None
APR  C 201 (-3.5A)
APR  C 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A  97
ALA A  50
1.53A
APR  A 201 (-4.0A)
None
None
APR  A 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PRO C 125
GLY C  48
ALA C 129
GLN C  62
1.54A
None
APR  C 201 (-3.5A)
APR  C 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  47
ALA B 129
GLN B  62
1.61A
None
APR  B 201 (-4.0A)
APR  B 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wqd NSP8
(SARS-CoV-2)		4 / 7
ILE D 120
PRO D 121
ALA D 152
GLN D 158
1.15A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wqd NSP8
(SARS-CoV-2)		4 / 7
ILE B 120
PRO B 121
ALA B 152
GLN B 158
1.13A
None
None
EDO  B 302 ( 4.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6y2f REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PRO A 108
GLY A 174
ALA A 129
GLN A 192
1.37A17.80
None
None
None
DMS  A 501 ( 3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PRO A 108
GLY A 174
ALA A 129
GLN A 192
1.34A10.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 7
ILE D 120
PRO D 121
ALA D 152
GLN D 158
1.16A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 7
ILE B 120
PRO B 121
ALA B 152
GLN B 158
1.36A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 7
ILE B  30
ALA A 372
GLU L  87
GLN B   3
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
ARG A 131
GLY A 109
GLU A 240
GLN A 127
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6yor IGG H CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 7
ILE E 410
GLY E 504
ALA E 435
GLN B  82
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6yor IGG H CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 7
ILE A 410
GLY A 504
ALA A 435
GLN H  82
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PRO A 108
GLY A 174
ALA A 129
GLN A 192
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE C  23
PRO C 125
GLY C 130
ALA C  50
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE C  23
PRO C 125
GLY C 130
ALA C  52
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE E  23
PRO E 125
GLY E 130
ALA E  50
1.46A
EDO  E 205 (-4.2A)
None
EPE  E 202 ( 4.5A)
EPE  E 202 (-3.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  52
1.50A
None
None
EDO  A 202 ( 4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO D 125
GLY D  48
ALA D 129
GLN D  62
1.50A
None
EDO  D 209 ( 4.7A)
EDO  D 205 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE C  23
PRO C 125
GLY C  97
ALA C  50
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO E 125
GLY E  48
ALA E 129
GLN E  62
1.47A
None
EPE  E 202 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE D  23
PRO D 125
GLY D 130
ALA D  50
1.47A
EDO  D 208 (-4.0A)
None
EDO  D 205 ( 4.9A)
EDO  D 206 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO C 125
GLY C  47
ALA C 129
GLN C  62
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE E  23
PRO E 125
GLY E 130
ALA E  52
1.50A
EDO  E 205 (-4.2A)
None
EPE  E 202 ( 4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B  97
ALA B  50
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  47
ALA A 129
GLN A  62
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  97
ALA A 129
GLN D 118
1.76A
None
EDO  A 202 ( 4.9A)
None
EDO  D 201 ( 4.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B 130
ALA B  50
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B 130
ALA B  52
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO C 125
GLY C  48
ALA C 129
GLN C  62
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO E 125
GLY E  48
ALA E 129
GLN E  62
1.47A
None
EPE  E 202 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE D  23
PRO D 125
GLY D  97
ALA D  50
1.47A
EDO  D 208 (-4.0A)
None
None
EDO  D 206 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO D 125
GLY D  97
ALA D 129
GLN A 118
1.68A
None
None
EDO  D 205 (-4.5A)
EDO  D 201 ( 4.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO C 125
GLY C  48
ALA C 129
GLN C  62
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO D 125
GLY D  48
ALA D 129
GLN D  62
1.49A
None
EDO  D 209 ( 4.7A)
EDO  D 205 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  50
1.47A
None
None
EDO  A 202 ( 4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO E 125
GLY E  47
ALA E 129
GLN E  62
1.65A
None
EPE  E 202 (-4.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A  97
ALA A  50
1.53A
None
None
EDO  A 202 ( 4.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO D 125
GLY D  47
ALA D 129
GLN D  62
1.71A
None
EDO  D 206 (-4.5A)
EDO  D 205 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  47
ALA B 129
GLN B  62
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO D 125
GLY D  48
ALA D 129
GLN D  62
1.52A
None
EDO  D 204 ( 3.4A)
APR  D 201 (-3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  97
ALA A 129
GLN D 118
1.59A
None
None
APR  A 201 ( 3.7A)
EDO  A 207 ( 4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  47
ALA A 129
GLN A  62
1.62A
None
APR  A 201 (-4.1A)
APR  A 201 ( 3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO E 125
GLY E  48
ALA E 129
GLN E  62
1.51A
None
APR  E 201 (-3.4A)
APR  E 201 (-3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO D 125
GLY D  97
ALA D 129
GLN A 118
1.57A
None
None
APR  D 201 (-3.4A)
EDO  D 203 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A  97
ALA A  50
1.48A
APR  A 201 (-3.9A)
None
None
APR  A 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.53A
None
APR  B 201 (-3.5A)
APR  B 201 (-3.6A)
EDO  B 202 (-4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B 130
ALA B  52
1.53A
APR  B 201 (-4.1A)
None
APR  B 201 (-3.2A)
APR  B 201 ( 4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.51A
None
APR  A 201 (-3.4A)
APR  A 201 ( 3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO C 125
GLY C  47
ALA C 129
GLN C  62
1.67A
None
APR  C 201 (-4.3A)
APR  C 201 (-3.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE D  23
PRO D 125
GLY D 130
ALA D  50
1.45A
APR  D 201 (-3.9A)
None
APR  D 201 (-3.2A)
APR  D 201 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B  97
ALA B  50
1.50A
APR  B 201 (-4.1A)
None
None
APR  B 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE D  23
PRO D 125
GLY D  97
ALA D  50
1.47A
APR  D 201 (-3.9A)
None
None
APR  D 201 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO C 125
GLY C  48
ALA C 129
GLN C  62
1.50A
None
APR  C 201 (-3.5A)
APR  C 201 (-3.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE E  23
PRO E 125
GLY E 130
ALA E  52
1.53A
APR  E 201 (-4.1A)
None
APR  E 201 (-3.2A)
APR  E 201 ( 4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE E  23
PRO E 125
GLY E 130
ALA E  50
1.44A
APR  E 201 (-4.1A)
None
APR  E 201 (-3.2A)
APR  E 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO D 125
GLY D  47
ALA D 129
GLN D  62
1.67A
None
APR  D 201 ( 4.3A)
APR  D 201 (-3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE C  23
PRO C 125
GLY C 130
ALA C  50
1.45A
APR  C 201 (-3.9A)
None
APR  C 201 (-3.2A)
APR  C 201 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  50
1.45A
APR  A 201 (-3.9A)
None
APR  A 201 ( 3.2A)
APR  A 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE E  23
PRO E 125
GLY E  97
ALA E  50
1.50A
APR  E 201 (-4.1A)
None
None
APR  E 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.54A
None
APR  A 201 (-3.4A)
APR  A 201 ( 3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO D 125
GLY D  48
ALA D 129
GLN D  62
1.50A
None
EDO  D 204 ( 3.4A)
APR  D 201 (-3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  47
ALA B 129
GLN B  62
1.64A
None
APR  B 201 (-3.6A)
APR  B 201 (-3.6A)
EDO  B 202 (-4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE C  23
PRO C 125
GLY C  97
ALA C  50
1.48A
APR  C 201 (-3.9A)
None
None
APR  C 201 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO C 125
GLY C  48
ALA C 129
GLN C  62
1.53A
None
APR  C 201 (-3.5A)
APR  C 201 (-3.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B 130
ALA B  50
1.45A
APR  B 201 (-4.1A)
None
APR  B 201 (-3.2A)
APR  B 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.51A
None
APR  B 201 (-3.5A)
APR  B 201 (-3.6A)
EDO  B 202 (-4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO E 125
GLY E  47
ALA E 129
GLN E  62
1.64A
None
APR  E 201 (-4.4A)
APR  E 201 (-3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO E 125
GLY E  48
ALA E 129
GLN E  62
1.49A
None
APR  E 201 (-3.4A)
APR  E 201 (-3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B 130
ALA B  52
1.51A
EDO  B 202 (-4.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE C  23
PRO C 125
GLY C  97
ALA C  50
1.45A
EDO  C 206 (-4.1A)
None
None
MES  C 201 ( 3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  97
ALA A 129
GLN C 118
1.63A
None
None
None
EDO  A 204 (-4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO C 125
GLY C  48
ALA C 129
GLN C  62
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  47
ALA B 129
GLN B  62
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A  97
ALA A  50
1.52A
None
None
None
MES  A 201 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B  97
ALA B  50
1.50A
EDO  B 202 (-4.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  52
1.48A
None
None
MES  A 201 (-3.1A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  50
1.49A
None
None
MES  A 201 (-3.1A)
MES  A 201 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B 130
ALA B  50
1.51A
EDO  B 202 (-4.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO C 125
GLY C  48
ALA C 129
GLN C  62
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  47
ALA A 129
GLN A  62
1.68A
None
MES  A 201 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		7bv1 NSP8
(SARS-CoV-2)		4 / 7
ILE D 120
PRO D 121
ALA D 152
GLN D 158
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
PRO A 537
GLY A 345
ALA A 379
GLN A 357
1.45A
None